The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

Ruben A. Mesa; Susan Schwager; Deepti Radia; Andrea Cheville; Kebede Hussein; Joyce Niblack; Animesh D. Pardanani; David P. Steensma; Mark R. Litzow; Candido E. Rivera; John Camoriano; Srdan Verstovsek; Jeffrey Sloan; Claire Harrison; Hagop Kantarjian; Ayalew Tefferi

doi:10.1016/j.leukres.2009.01.035

The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

Ruben A. Mesa, Susan Schwager, Deepti Radia, Andrea Cheville, Kebede Hussein, Joyce Niblack, Animesh D. Pardanani, David P. Steensma, Mark R. Litzow, Candido E. Rivera, John Camoriano, Srdan Verstovsek, Jeffrey Sloan, Claire Harrison, Hagop Kantarjian, Ayalew Tefferi

Research output: Contribution to journal › Article › peer-review

151 Scopus citations

Abstract

Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.

Original language	English (US)
Pages (from-to)	1199-1203
Number of pages	5
Journal	Leukemia Research
Volume	33
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2009.01.035
State	Published - Sep 2009

Keywords

Fatigue
Myelofibrosis
Myeloproliferative disorder
Primary myelofibrosis
Splenomegaly

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2009.01.035

Cite this

Mesa, R. A., Schwager, S., Radia, D., Cheville, A., Hussein, K., Niblack, J., Pardanani, A. D., Steensma, D. P., Litzow, M. R., Rivera, C. E., Camoriano, J., Verstovsek, S., Sloan, J., Harrison, C., Kantarjian, H., & Tefferi, A. (2009). The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 33(9), 1199-1203. https://doi.org/10.1016/j.leukres.2009.01.035

Mesa, RA, Schwager, S, Radia, D, Cheville, A, Hussein, K, Niblack, J, Pardanani, AD, Steensma, DP, Litzow, MR , Rivera, CE , Camoriano, J, Verstovsek, S, Sloan, J, Harrison, C, Kantarjian, H & Tefferi, A 2009, 'The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis', Leukemia Research, vol. 33, no. 9, pp. 1199-1203. https://doi.org/10.1016/j.leukres.2009.01.035

@article{24a3f537a47a4087841d97de4d2f4297,

title = "The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis",

abstract = "Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.",

keywords = "Fatigue, Myelofibrosis, Myeloproliferative disorder, Primary myelofibrosis, Splenomegaly",

author = "Mesa, {Ruben A.} and Susan Schwager and Deepti Radia and Andrea Cheville and Kebede Hussein and Joyce Niblack and Pardanani, {Animesh D.} and Steensma, {David P.} and Litzow, {Mark R.} and Rivera, {Candido E.} and John Camoriano and Srdan Verstovsek and Jeffrey Sloan and Claire Harrison and Hagop Kantarjian and Ayalew Tefferi",

year = "2009",

month = sep,

doi = "10.1016/j.leukres.2009.01.035",

language = "English (US)",

volume = "33",

pages = "1199--1203",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - The Myelofibrosis Symptom Assessment Form (MFSAF)

T2 - An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

AU - Mesa, Ruben A.

AU - Schwager, Susan

AU - Radia, Deepti

AU - Cheville, Andrea

AU - Hussein, Kebede

AU - Niblack, Joyce

AU - Pardanani, Animesh D.

AU - Steensma, David P.

AU - Litzow, Mark R.

AU - Rivera, Candido E.

AU - Camoriano, John

AU - Verstovsek, Srdan

AU - Sloan, Jeffrey

AU - Harrison, Claire

AU - Kantarjian, Hagop

AU - Tefferi, Ayalew

PY - 2009/9

Y1 - 2009/9

N2 - Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.

AB - Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.

KW - Fatigue

KW - Myelofibrosis

KW - Myeloproliferative disorder

KW - Primary myelofibrosis

KW - Splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=67549104035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549104035&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.01.035

DO - 10.1016/j.leukres.2009.01.035

M3 - Article

C2 - 19250674

AN - SCOPUS:67549104035

SN - 0145-2126

VL - 33

SP - 1199

EP - 1203

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this